Matt Hoffman

Robert Zivadinov, MD, PhD, director, Buffalo Neuroimaging Analysis Center, spoke to the findings of a post-hoc analysis of atrophied T2-lesion volume as a biomarker in patients with progressive MS.

Data presented at SLEEP 2021 from Study 303 suggest that long-term use of lemborexant is well received by patients, who reported that the agent helped them fall asleep and improved total sleep time.

Deena Kuruvilla, MD, the medical director of the Westport Headache Institute spoke to the potential of e-TNS in the treatment of migraine overall and which gaps in care that it might fill.

The calcium, magnesium, potassium, and sodium oxybates oral solution, marketed as Xywav, is currently also under review for the treatment of idiopathic hypersomnia, with an FDA decision expected by August 12, 2021.

The CEO of CENTOGENE discussed the recently announced EFRONT study in FTD and the role that rare disease genetic data collection can play in providing insights into disease intervention and treatment.

The Idorsia dual orexin receptor antagonist was accepted by the FDA for review in March 2021 and has shown efficacy in a number of SLEEP 2021 poster presentations.

Luca Giliberto, MD, PhD, and Cristina d’Abramo, PhD, share more than a marriage: After years of research, their combined efforts to develop a passive immunotherapy for Alzheimer disease have earned them a $2 million grant from the National Institutes of Health.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Michael J. Thorpy, MD.

Biogen’s investigational antibody against the N-terminus of tau failed to meet any of the efficacy or exploratory end points in individuals with mild cognitive impairment or mild Alzheimer disease.

Two experts in pediatric MS care, Lauren B. Krupp, MD, and Tanuja Chitnis, MD, offer tips and insight on the diagnosis of the disease and the specific challenges faced by patients stemming from their own clinical experience.

Here's what is coming soon to NeurologyLive.

The task force assessed 6 total interventions, all of which received conditional recommendations aside from cognitive behavioral therapy for insomnia, which was strongly recommended.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive look into the FDA approval of aducanumab (Aduhelm; Biogen) for the treatment of Alzheimer disease.

Experts in the treatment and management of patients with Alzheimer disease and dementia, including Marwan Sabbagh, MD; Lon Schneider, MD, MS; Anton Porsteinsson, MD; and Robert Howard, MD, MRCPsych, weigh in on the FDA's controversial approval of Biogen's anti-amyloid drug, aducanumab.

The FDA has approved Biogen’s disease-modifying, anti-amyloid agent aducanumab after a tumultuous regulatory journey.

Using the FDA-approved Cefaly device, the TEAM study data suggest that the device can be applied as a safe alternative to pharmacological treatments in the acute treatment of migraine.

An assessment of data from the PROMISE-2 trial suggests that individuals who respond to treatment in the first month are likely to maintain their response through at least 6 months.

Open-label data of concomitant use of CGRP monoclonal antibodies and receptor antagonists suggest that the agents can be safely and effectively combined in the treatment of migraine.

Respondents reported varying levels of comfort regarding the management of migraine during pregnancy, with only half of women’s healthcare providers indicating they conducted counseling on migraine during pregnancy.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Barry Hendin, MD.

Identified by Mayo Clinic investigators, the protein-coding gene SERPINA5 was found to be associated with tau expression, characteristic of Alzheimer disease pathology.

Marisa McGinley, DO, from the Mellen Center for Multiple Sclerosis Treatment and Research at Cleveland Clinic, offered her insight into the manual dexterity test and the need to better prognosticate dexterity issues.

Biohaven’s agent is now the first oral CGRP antagonist to be approved for prevention, and the first to be approved for both acute and preventive therapy. It is marketed as Nurtec ODT and is administered in a 75-mg dose.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Matthew B. Harms, MD.

Sleep depth was observed to be an independent predictor of heart rate change following seizure for patients with epilepsy.

Improvements in DMTs and management standards appear to have lowered the risk of progression to EDSS scores of 4.0 and 6.0 for those with pediatric-onset disease.

The Epilepsy Digital Experience Navigator, or EDEN, platform, is being developed in tandem with Embleema, with an aim of improving data use and collection for individuals with epilepsy.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Elyse Stock, MD, and Thomas Shiovitz, MD.

Two experts in spinal muscular atrophy (SMA) care, Diana Castro, MD, and Garey H. Noritz, MD, offer tips and demonstrations for screening and diagnosing SMA via telehealth, and they outline resources provided by Cure SMA for families and clinicians who suspect, or have a patient with a diagnosis of, SMA.

The chief scientific officer of the Parkinson’s Foundation and adjunct associate professor in the Department of Neuroscience and Physiology at New York University School of Medicine discussed the adoption of telemedicine in Parkinson disease care.